Truist: Generative AI will bring opportunities in the fields of infrastructure and network security, raising the target price for CrowdStrike (CRWD.US).
Before several infrastructure and security software companies announced their quarterly results, Truist Securities adjusted its target price.
Before several infrastructure and cybersecurity companies announced their quarterly results, Truist Securities adjusted their target prices.
Lead analyst Joel Fishbein Jr. stated that they believe buyer behavior has stabilized in the infrastructure and cybersecurity sectors since last year. They are focused on visibility for the year 2025, predicting that this is when generative artificial intelligence projects will face a "litmus test".
With the rise in valuations since the U.S. presidential election, analysts anticipate high costs for execution errors in the coming weeks. Therefore, high-quality stocks will be favored, including Snowflake (SNOW.US) and Zscaler (ZS.US), both of which received a "buy" rating from the firm.
In general, the Truist rating adjustments are as follows:
CrowdStrike (CRWD.US): "Buy" rating, target price adjusted from $325 to $375.
Palo Alto Networks (PANW.US): "Buy" rating, target price adjusted from $400 to $425.
Rubrik (RBRK.US): "Buy" rating, target price adjusted from $43 to $50.
Samsara (IOT.US): Target price adjusted from $40 to $50, reaffirming a "hold" rating.
Related Articles

Tracking Hong Kong concept stocks | Global shipping giants collectively raise prices, airline profits may further increase (with concept stocks)

Anhui Anke Biotechnology (300009.SZ): Innovative drug HuA21 injection to release clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting.

China Securities Co., Ltd.: First-tier cities in September maintain high land premium rates, optimistic about high-quality commercial real estate companies.
Tracking Hong Kong concept stocks | Global shipping giants collectively raise prices, airline profits may further increase (with concept stocks)

Anhui Anke Biotechnology (300009.SZ): Innovative drug HuA21 injection to release clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting.

China Securities Co., Ltd.: First-tier cities in September maintain high land premium rates, optimistic about high-quality commercial real estate companies.

RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025